Despite the growing evidence for the importance of the complement system in the normal as well as diseased brain, there are only a few studies investigating the changes in complement proteins and their activation product levels in the systemic circulation of ischemic stroke patients [20]–[23], [26], [30] and in particular the relevance of these alterations for short and long term outcome [20], [21], [23], [26]. This evidence concerns the gene VTN and ischemic stroke.